News & Events

Upcoming Conferences

: Boston, MA, USA
: September 22, 2025
: September 25, 2025
: Cambridge Healthtech Institute
:

  • Novel drug targets (cancer therapies, protein degradation, GLP-1/obesity targets)

  • Emerging modalities (ADCs, bispecifics, AI/machine learning in target identification)

  • Translational models and synthetic biology
    : https://www.discoveryontarget.com1

: Barcelona, Spain
: April 7, 2025
: April 8, 2025
: UBIQ Events
:

  • AI-driven drug discovery and clinical trial optimization

  • Personalized medicine and regulatory/ethical considerations

  • Commercial applications of AI in pharma
    : https://www.pharmameetsai.com2

: Amsterdam, Netherlands
: May 7, 2025
: May 8, 2025
: REMEDi4ALL and Beacon
:

: Edison, NJ, USA
: April 7, 2025
: April 9, 2025
: New England Statistical Society
:

  • AI-powered drug development and clinical operations

  • Pharmacovigilance, regulatory compliance, and digital health solutions

  • Interdisciplinary applications of machine learning in pharma
    : https://phds.nestat.org468

: Berlin, Germany
: April 28, 2025
: April 30, 2025
: Helmholtz Association
:

: Amsterdam, Netherlands
: September 23, 2025
: September 24, 2025
: Future Pharma Organizing Committee
:

  1. : Every major conference now includes dedicated tracks for AI applications, reflecting its transformative role in target identification1, clinical trial design6, and drug repurposing3.

  2. : iDR25 and PharmaDS emphasize patient-driven trial designs and ethical AI deployment36, aligning with regulatory shifts toward personalized medicine.

  3. : Events like Helmholtz and Pharma Meets AI bridge academia, biotech, and pharma to address challenges in RNA therapeutics5 and data interoperability9.

Recent Conferences – Notes and Impressions

Startup Funding Fundamentals - Wilmer & Snell

Here’s a high-level summary of the key themes and advice presented by Roger Rappaport on startup fundraising strategy:

1. Importance of a Comprehensive Funding Strategy

  • Aligned Planning: Your funding plan should be integrated with product development, sales and marketing, IP strategy, and organizational growth. Each element should work in concert so you don’t outpace your financial runway or become “unfundable” by running out of cash prematurely.
  • Inflection Points: Identify and time your fundraising around clear value inflection points—moments when the company’s worth demonstrably increases. This allows you to raise capital on better terms.

2. Choosing the Right Investors and Terms

  • Investor Fit: Don’t just chase capital; seek investors whose goals, expertise, and stage focus align with your company’s roadmap. A misaligned investor can lead to wasted effort, loss of control, or strategic derailment.
  • Control and Dilution: Without a well-considered strategy, founders risk excessive dilution and losing control, often by as early as Series B. Investors may eventually replace founding CEOs with professional managers.
  • Valuation and Option Pools: Valuation isn’t just a headline number—it’s tied to how large your option pool must be. Larger pools dilute founders, so plan carefully. Model your organizational chart and hiring needs over the next few years to size the pool correctly and negotiate more favorable terms.

3. Funding Instruments and Their Implications

  • Types of Securities: Common fundraising vehicles include preferred equity, convertible notes, and SAFEs. Each has distinct advantages, disadvantages, and potential pitfalls.
  • Preferred Stock: Preferred shares usually come with specific rights and protections for investors. Be careful not to give away disproportionate rights at early stages.
  • Convertible Notes and SAFEs: While flexible, these instruments can be tricky. Post-money SAFEs, in particular, can be unexpectedly dilutive if you raise more capital than anticipated before a priced round.
  • Avoid Common Stock Sales to Investors: Selling common stock too early can create valuation complications and limit the effectiveness of stock options as employee incentives.

4. IP Strategy as Part of Fundability

  • Moat and Value: Strong IP protection can influence investor perception and valuation. If first-to-market advantage is eroded by lack of IP, the company’s strategy (and funding path) must adapt.
  • Patent Timing: Consider provisional patents to secure priority dates and maintain flexibility. International filings and patent strategy should align with key growth milestones and fundraising rounds.

5. Avoiding Common Pitfalls

  • Over-Dilution and Wrong Terms: Early fundraising mistakes can become permanent, forcing founders out and diminishing their ultimate returns.
  • Not Getting Counsel Early: Signing a term sheet without legal guidance can lock you into unfavorable terms that can’t be easily corrected later.
  • Unrealistic Capital Needs: Stating arbitrary large funding requirements without clear milestones or justification raises investor suspicion and weakens your negotiating position.

6. Funding Sources and Considerations

  • Friends & Family, Angels, and Grants: These can help reach early milestones but should be used sparingly to prevent excessive dilution at a low valuation.
  • Venture Capital and Venture Debt: VC firms often require certain rights and board seats. Venture debt can be less dilutive but comes with repayment obligations.
  • Strategic Investors: Corporate or strategic backers can offer market access and support but may demand restrictive terms (e.g., rights of first refusal).

7. Valuation and Negotiation

  • Market and Stage-Based Valuations: Use industry benchmarks, comparable transactions, and realistic forecasts to establish valuations.
  • 20–30% Dilution Norm: Typical early rounds often involve giving up 20-30% equity—structure raises and milestones accordingly.
  • Investor Alignment and Diligence: Understand investor motives. Are they short-term flippers or long-term partners aligned with your vision?

In essence:
The presentation emphasized the need for a well-defined, strategic approach to fundraising—one that integrates product, people, IP, and finance. Founders must understand the implications of each funding source, instrument, and legal term to avoid losing control, over-diluting, and undermining their company’s long-term potential. Thoughtful planning, realistic milestones, IP strategy, careful choice of investors, and proactive legal guidance are all essential ingredients for successful and sustainable fundraising.

2024 SAMPS - Life Science Marketing Conference

What We Learned About Life Science Marketing at SAMPS 2024

Change is happening fast, and if there’s one thing everyone at the SAMPS 2024 conference agreed on, it’s that innovation is key. But here’s the catch: while everyone wants innovation, most people aren’t ready to change. Hamid Ghanadan from LINUS put it best: real innovation happens when it’s woven into the fabric of every part of a company—not just R&D or marketing. Whether it’s shaking up a business model, like subscription-based services, or creating entirely new experiences, like HelloFresh did with pre-measured meal kits, it’s all about adding value where it matters most.

Get Inside Your Customer’s Brain

If you want your message to stick, it helps to understand how people think. Ghanadan shared seven brain hacks that are gold for marketers. For example, reciprocity (“You scratch my back, I’ll scratch yours”) makes customers feel valued. Scarcity? That’s the FOMO factor—people want what they can’t have. And don’t forget authority; when a credible expert says it, people listen. The trick is weaving these principles into your messaging so it resonates, whether you’re targeting early adopters or those lagging behind.

Personalization: The New Normal

Personalization isn’t just a buzzword anymore; it’s a must-have. Jessica Kao from Cloudflare showed how account-based marketing (ABM) can make your outreach feel personal at scale. Using real-time data—like what a customer is searching for or which trade shows they’ve attended—lets you tailor your pitch. It’s all about being in the right place at the right time with the right message. Bonus: automation tools can handle the heavy lifting so your team focuses on what really matters—building relationships.

Tell a Story, Don’t Just Sell a Product

People don’t remember product specs, but they do remember stories. Jen Perkins from Crevi nailed it when she said your brand narrative should be bigger than your product. It’s not about what you sell; it’s about the problem you’re solving and how you see the world. Take Emulate’s organ-on-chip tech—they told a story about fixing inefficiencies in drug development, which got them not just sales, but attention from the FDA and media outlets like The New York Times. That’s the power of storytelling.

Teams That Work Together, Win Together

Marketing, sales, and customer success teams can’t afford to work in silos. Panelists shared how aligning everyone around shared goals creates smoother processes and bigger wins. Tools like Folloze and Calendly help bridge the gap, but at the end of the day, it’s about culture. If everyone isn’t rowing in the same direction, you’re leaving money on the table.

Adapt or Get Left Behind

The world has changed—post-COVID challenges, economic uncertainty, and shifting workforce dynamics are the new normal. The companies that win will be the ones that embrace these challenges head-on. Scenario planning was a big topic at the conference, and it’s all about asking, “What can we control?” A unified strategy, customer-first thinking, and flexibility are non-negotiables.

It’s All About the Experience

Your brand is more than your product—it’s every single touchpoint with your customers. Whether it’s launching smart tools like IDT’s LabLinker or creating seamless online-offline integration, today’s customers expect convenience and personalization. The takeaway? Don’t just keep up with the times; find ways to stay a step ahead.

In a nutshell, SAMPS 2024 reminded us that great marketing isn’t about shouting louder; it’s about connecting smarter. By blending innovation, empathy, and teamwork, life science marketers can cut through the noise and deliver real value.

AI-Driven Drug Development

Expanding from Drug Discovery to the broder scope of Drug Development, Kisaco Research’s “AIDDD” conference (Boston, November 2024) showed the expanding appeal of AI and machine learning across all pharmaceutical segments. 

Human Tumor Atlas Network (Nature)

Nature published the Human Tumor Atlas Network to expand spatial understanding of molecular, cellular and tissue features. HTAN offers a multidimensional view of cancer...

San Diego’s Iambic Therapeutics releases AI platform for better outcome predictions

Iambic's AI-driven Enchant™ platform predicts clinical outcomes better than industry standard—from the discovery stage of drug development. Utilizing early discovery...

Takeaways from Festival of Biologics (San Diego)

April 2024 - Festival of Biologics (Terrapin, San Diego) featured exciting talks on genAI for clinical trials. Here are a few intriguing takeaways: Trial challenges are...